Instrument Inactif

Communiqués Immunomedics, Inc.

Actions

IMMU

US4529071080

Recherche biotechnologique et médicale

Communiqués

23/10/20	IMMUNOMEDICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
12/10/20	Immunomedics : Announces FDA Orphan Drug Designation of Trodelvyᵀᴹ for Glioblastoma	PU
12/10/20	Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma	GL
12/10/20	Immunomedics : Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma	AQ
26/09/20	WeissLaw LLP : Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing Investigations	PR
21/09/20	IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21/09/20	(IMMU) Alert: Johnson Fistel Investigates Proposed Sale of Immunomedics; Is $88 a Fair Price?	PR
19/09/20	Immunomedics : Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer	PU
19/09/20	Immunomedics : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvyᵀᴹ in Metastatic Urothelial Cancer	PU
19/09/20	Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer	GL
19/09/20	Immunomedics : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer	AQ
19/09/20	Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer	GL
19/09/20	Immunomedics : Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer	AQ
18/09/20	Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers	GL
18/09/20	Immunomedics : Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers	AQ
17/09/20	IMMUNOMEDICS INC : Change in Directors or Principal Officers (form 8-K)	AQ
14/09/20	Immunomedics : Wall Street posts solid gains after surge in corporate deals	AQ
14/09/20	IMMUNOMEDICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Immunomedics - IMMU	BU
14/09/20	Immunomedics : Gilead Sciences buying Immunomedics in $21 billion deal	AQ
14/09/20	IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/09/20	Immunomedics : Gilead Sciences buying Immunomedics in $21 billion deal	AQ
13/09/20	Immunomedics : Gilead Sciences to Acquire Immunomedics	BU
09/09/20	Immunomedics : Announces Key Oral Presentations at ESMO 2020	PU
09/09/20	Immunomedics : Announces Key Oral Presentations at ESMO Virtual Congress 2020	AQ
09/09/20	Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020	GL